Login to Your Account

FDA Panel: Revoke Avastin's Approval in Breast Cancer

By Donna Young

Wednesday, July 21, 2010
GAITHERSBURG, Md. – An FDA panel of oncology experts Tuesday said Genentech Inc. and its parent company Roche AG should no longer be permitted to market Avastin (bevacizumab) in the U.S. as a treatment in combination with chemotherapy for HER2-negative metastatic breast cancer, agreeing that the firm's follow-up studies failed to confirm the magnitude of improvement in progression-free survival (PFS) observed in an earlier trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription